Associate Professor, Gastrointestinal Medical Oncology, MD Anderson Cancer Center #TranslationalResearch #ClinicalTrials #ColorectalCancer #AnalCancer #PI3K
Houston
Joined March 2015
- Tweets75
- Following129
- Followers173
- Likes241
Maliha Nusrat retweeted
Young-onset colorectal cancer is rising, and CRC demands focus. @MDAndersonNews has created a dedicated Department of Colorectal Medical Oncology to meet that challenge. Honored to serve as its inaugural Chair and partner with new GI Med Onc chair Arvind Dasari @adasarimd #CRCSM
For all patients with biliary cancers who need a cure, in perpetual support of those who have dedicated their youth to finding a cure.
Kudos to @rachnatshroff for leading the way! Join in 👇
support.conquer.org/p2p/site…
So fortunate to have witnessed this historic moment! Kudos to the chemists, biologists, clinical investigators, investors, advocates who persevered over decades - an inspiration to researchers everywhere and a hope for the patients 👏🏻👏🏻👏🏻
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer
Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived
#ASCO26
Maliha Nusrat retweeted
Yesterday, we were thrilled to reunite with Winn Career Development Award alumni, scholars, and funding partners at #ASCO2026 in Chicago! It was a truly special opportunity to come together and celebrate the impact we are collectively making in communities across the nation.
What an inspiring night seeing my mentor @skopetz receive 2026 Giants in Cancer Care award, and listening to him share what inspires him. His tireless efforts have changed the standard of care treatment for patients with CRC multiple times, and more work is ongoing. Congrats!
Maliha Nusrat retweeted
A 𝐧𝐞𝐨𝐚𝐧𝐭𝐢𝐠𝐞𝐧 is a novel peptide that is derived from a somatic variant in a tumor cell and can be recognized as “nonself” by T cells. Neoantigens are tumor-specific and have not been encountered during thymic T-cell development and are therefore not subject to central tolerance.
To learn more about this NEJM Illustrated Glossary term, read the Clinical Implications of Basic Research article “Understanding How Aspirin Prevents Metastasis” by Ruth E. Langley, MB, BS, PhD, and John Burn, MD, from University College London and @uniofnewcastle: nej.md/4pTzyaw
Explore more terms: nej.md/glossary
ALT Visual representation of a neoantigen
Maliha Nusrat retweeted
🔥10 Must-Read Posts in GI Oncology | Last week of February
Updates across gastroesophageal (gastric/GEJ), PDAC, CRC, BTC, and esophageal cancer—spanning guidelines, translational profiling, real-world data, and surgical perspectives.
• FGFR inhibitors in cholangiocarcinoma (FGFR2, resistance, cfDNA)
• ASCO guideline update: advanced gastroesophageal cancer (HER2/PD-L1/MSI-MMR/CLDN18.2)
• KEYNOTE585: early endpoints in periop pembro+chemo (gastric/GEJ)
• JCOG0603: adjuvant chemo vs hepatectomy alone (CRC liver mets)
• SUNLIGHT: FTD–TPI+bev vs FTD–TPI (mCRC)
• Stage-resolved transcriptomic atlas of PDAC progression
• CGD-treated BTC: metastatic-site prognostic analysis
• Feeding adjuncts in oesophagogastric cancer resection
• Radiation oncology update (Marburg Ion-Beam Therapy Center)
• Rare pathogenic variants in esophageal cancer markers (computational study)
Takeaway: Biomarkers, stage-aware biology, and real-world validation continue to shape GI oncology practice.
@NelsonDusetti @KoheiShitara @ErulEnes @Sarbaji85064063 @casadei_gardini
oncodaily.com/oncolibrary/10…
#GIOncology #Cholangiocarcinoma #GastricCancer #PancreaticCancer #CRC #EsophagealCancer #PrecisionOncology #BiliaryTractCancer #GEJ
Maliha Nusrat retweeted
🔥𝗠𝗼𝗻𝘁𝗵𝗹𝘆 GI 𝗖𝗮𝗻𝗰𝗲𝗿 𝗨𝗽𝗱𝗮𝘁𝗲𝘀 — 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟲
February brought important advances across all stages of colorectal cancer — from screening to biomarker-driven metastatic care.
Key highlights
• Phase III CONVERT (MRI-selected LARC)
• Real-world FTD–TPI + bevacizumab validation
• SCREESCO screening RCT update
• Liver metastases as negative predictor for ICI in MSS mCRC
• FDA approval: encorafenib triplet (1L BRAF V600E mCRC)
• FDA Fast Track: pelareorep (2L KRAS-mut MSS)
• SPC risks in non-hereditary CRC survivors
• JSKN003 Phase III (HER2+ CRC)
• ABACO Phase II (cabozantinib, refractory MSS mCRC)
• Inferior post-metastasectomy outcomes in early-onset CRC
Precision CRC care continues to evolve.
@oncodaily @skopetz @CathyEngMD @TaberneroJosep @FilippoPietran4 @sara_lonardi1 @ChiaraCrem1 @TarazonaNoelia
👉 oncodaily.com/oncolibrary/co…
#ColorectalCancer #GIOncology #mCRC #PrecisionOncology
How do patients with mCRC and ECOG PS2 tolerate FTD-TPI+bev? We found that outcomes and AEs of patients with PS2 and PS 0-1 were comparable in real-world data and in pooled data from TASCO1 and SOLSTICE trials. @JCOOA_ASCO #CRC ascopubs.org/doi/10.1200/OA-…
Our analysis of a heterogeneous US-based real world dataset shows longer OS with FTD–TPI+bevacizumab vs FTD–TPI in patients with metastatic CRC, similar to the results of the phase 3 SUNLIGHT trial. #NEJMEvidence #CRC
evidence.nejm.org/doi/full/1…
Sharing insights on the management of ultra-rare metastatic mucinous tailgut cyst adenocarcinoma.
We pursued patient-oriented biomedical science for one patient, because every patient matters.
frontiersin.org/journals/onc…
Maliha Nusrat retweeted
Congrats to Dr. @debschrag, the Department of Medicine's fearless leader, on being elected as the 2027–2028 @ASCO President! She has devoted her career to accelerating progress for people with #cancer, and we can't wait to witness the amazing things she will do next. #oncology
👏 Congratulations to Dr. @debschrag, a gastrointestinal medical oncologist at MSK and Chair of the @MSK_DeptOfMed, on being elected as the 2027-28 President of @ASCO.
Dr. Schrag will take office as President-Elect following the conclusion of the ASCO Annual Business Meeting in Chicago on June 1, 2026.
“ASCO is at the forefront of cancer care and empowers the global oncology community by bringing us together to drive innovation and discovery and tackle challenges that enable us to improve outcomes for our patients” said Dr. Schrag. “I thank ASCO’s membership for trusting me with this important responsibility and look forward to advancing ASCO’s strategic plan and championing the shared values of the oncology workforce to accelerate progress in partnership with the Society’s members.”
Read more: bit.ly/4p1Yhsw
I am excited to share our framework, challenges and solutions for decentralizing a phase 1 clinical trial throughout our regional care network. #OneMSK It’s feasible and saves a ton of valuable patient time.
#ASCOQLTY25 Poster B11.
ascopubs.org/doi/10.1200/OP.…
@WinnAwards
Maliha Nusrat retweeted
Tumor inflammation predicts better response to nivolumab alone in MSI-H CRC, while high mutational burden predicts benefit from nivolumab + ipilimumab. Our Nat Comm paper dives into CM142 and PD1 ± CTLA4 predictors with lead of @michael_overman. rdcu.be/eJHmS #crcsm
Maliha Nusrat retweeted
Strong @AKUGlobal representation @ASCO 25! @SyedKazmiMD @ShaalanBeg @malihanusr @NausheenAhmedMD @pashtoonkasi @SeharVirani @shameel_shafqat and others!
Maliha Nusrat retweeted
Congratulations to our team. Next chapter in Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine nejm.org/doi/10.1056/NEJMoa2…
Maliha Nusrat retweeted
Neoadjuvant botensilimab + balstilimab in MSI & MSS CRC #ESMOGI24
🔎NEST clinical trial, 20 MSS, 3 MSI
👉pMSS: 50% cPCR rate
🧐Really active in MSI & MSS CRC
#ESMOAmbassadors @myESMO
Maliha Nusrat retweeted
📢Adjuvant celecoxib in PIK3CA-Activated Stage III Colon Cancer
➡️Alliance trial update
➡️Compared to wild-type tumors,
✅DFS: aHR: 0.56 (0.33 to 0.96)
✅OS: aHR: 0.44 (0.22 to 0.85)
👉doi.org/10.1200/JCO.23.01680
@JCO_ASCO @JCOPO_ASCO @JCOOP_ASCO @GlobalCRC @CCAlliance @OncoAlert
#oncology #cancer #colorectal #MedX
Congratulations to Dr. Kopetz on this outstanding accomplishment! Dr. Hong would be so proud!
We congratulate the recipient of the AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research, Scott Kopetz, MD, PhD.
Dr. Kopetz will present his Award Lecture at #AACR24 on Sunday April 7, 4:30-5:15 PM. Learn more: bit.ly/3TEwaSz
